Noble Joins the Human Factors MEdical DevIce Consortium

March 9, 2021

Noble, an Aptar Pharma company, has joined the Human Factors MEdical DevIce Consortium (hfMEDIC), whose mission is to engage industry and universities in a partnership to develop safer and more effective medical devices through human-centered design.

Led by the University of Utah, the consortium also includes academic partners North Carolina State University, Rice University, San Jose State University and the University of Maryland, and industry partner AbbVie.

The global market for medical devices is approximately $436 billion, bolstered by an aging global population, according to data from hfMEDIC. The associated cost estimate of human error, based on the percentage of errors attributed to human error from the U.S. Food and Drug Administration (FDA) recall and adverse event databases, is $48 million annually, with most due to labeling design, employee error and software-use environment issues.

hfMEDIC envisions an integrated multi-disciplinary team that builds on the strengths and resources of all stakeholders (for example, patients, healthcare providers, industry, academia and regulators) to address this critical need to reduce errors through human-centered design. The Institute of Medicine has recognized that the solution must include human factors, a scientific discipline that considers the limitations and capabilities of the people who use the devices so that the design results in accurate and safe performance. These limitations can be addressed by bringing together the expertise and resources of universities and industries, which is the purpose of hfMEDIC.

Noble, a world leader in providing drug delivery training device solutions for biopharmaceutical companies and original equipment manufacturers, recently expanded its services to include Human Factors Engineering (HFE). In doing so, Noble aims to better help its customers meet the needs of their patients by advancing the development and testing of self-administered medical products to optimize safety and efficacy while minimizing use errors and the risk of adverse events. The benefits of Noble’s Human Factors Plus service offerings include producing easier-to-use devices, better patient understanding of how the devices operate, more effective and efficient training, improved patient compliance and medical outcomes, and the reduced risk of use error, product complaints and recalls.

 

“hfMEDIC is doing important work to connect the needs of the industry with the expertise of a network of researchers,” said Tim McLeroy, Noble’s executive director of marketing and patient services. “We’re honored to be a part of this consortium and serve as a consulting resource for medical device manufacturers looking to improve usability and safety of their products.”

 

SourceNoble.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version